We are live on ! Find out more
BIOL

Biolase, Inc.

Delisted

BIOL was delisted on the 18th of June, 2024.

35 hedge funds and large institutions have $42.2M invested in Biolase, Inc. in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 5 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more capital invested

Capital invested by funds: $33.3M → $42.2M (+$8.94M)

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

3% more funds holding

Funds holding: 3435 (+1)

29% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 7

97% less call options, than puts

Call options by funds: $1K | Put options by funds: $34K

Holders
35
Holders Change
+1
Holders Change %
+2.94%
% of All Funds
1.02%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
5
Reduced
7
Closed
5
Calls
$1K
Puts
$34K
Net Calls
-$33K
Net Calls Change
+$42K
Name Holding Trade Value Shares
Change
Change in
Stake
BRWA
51
B. Riley Wealth Advisors
Florida
-$2.89K
TRCT
52
Tower Research Capital (TRC)
New York
-$6K

BIOL Hedge Fund Activity: Q3 2014 in Review

35 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Biolase, Inc. (BIOL) for Q3 2014, worth a combined $42.2M — up 27% from $33.3M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new BIOL positions and 5 closed out — a net gain of 1 holder — while 5 added to existing stakes and 7 trimmed.

The largest buyer was Oracle Investment Management, adding an estimated $5.15M. The largest seller was Northern Trust, cutting an estimated $594K.

  • 35 institutional investors held Biolase, Inc. (BIOL) as of Q3 2014, up from 34 in Q2 2014.
  • Funds reported $42.2M of Biolase, Inc. stock for Q3 2014, up 27% quarter-over-quarter.
  • 6 funds opened new Biolase, Inc. positions in Q3 2014 and 5 closed out, a net change of +1 holder.
  • The largest Biolase, Inc. buyer in Q3 2014 was Oracle Investment Management, an estimated $5.15M added.
  • The largest Biolase, Inc. seller in Q3 2014 was Northern Trust, an estimated $594K sold.

Based on aggregated 13F filings for Q3 2014.